

PACE/CRDP PROVIDER BULLETIN

December 5, 2019

COMMONWEALTH OF PENNSYLVANIA DRUG MANUFACTURERS' REBATE PROGRAM NON PARTICIPATING MANUFACTURERS

Effective January 5, 2020, PACE and CRDP will no longer reimburse for products from the labelers listed below for failing to comply with the Commonwealth's rebate program.

Providers using products from these manufacturers may wish to explore alternative sources.

Labeler Number	Labeler Name	Medication (s) Affected
69784	Woodward Pharma Svcs LLC	polyethylene glycol 3350 powder
51801	Nomax Inc	Effer-K tablet effervescent
62559	ANI Acquisition Company	propranolol, hydrocortisone cream
70003	Jacksonville Pharmaceuticals, Inc	nitroglycerin lingual
24689	Apnar Pharma LP	bupirone
42388	Exelixis Inc	Cometriq®, Cabometyx®
60219	Amneal Pharmaceuticals	azathioprine
70428	Dermira Inc	Qbrexza®
70795	Graxcell Pharmaceuticals LLC	hydrocortisone suppository
71143	Optinose US Inc	Xhance® nasal spray
71717	Megalith Pharmaceuticals Inc	clopidogrel
72205	Novadoz Pharmaceuticals LLC	rosuvastatin
70114	Coherus Biosciences Inc	Udenyca®

Please direct any questions concerning this non-compliance decision to the appropriate manufacturer.